Skip to content
back
back
back
back
back
You are about to leave Fidia Pharma USA Inc.
All information you are about to see is related to a specific selected market, including the products’ portfolio, and therefore comply to different local regulations.
PROCEED
cta

About us

Our Group is an Italian multinational company, established in 1946, with a vocation to create solutions to meet new challenges in health and improve quality of life for people.

The strength of insight

We have understood the potential of hyaluronic acid since the 1950s and today we are one of the leading global players in the manufacture of hyaluronic acid-based products. Full control of the supply chain, from research to marketing, sets us apart and for this reason we define ourselves as a fully integrated company.

GLOBAL EMPLOYEES
+1,600
REVENUES IN 2023
463.5 € millions

“

It is always the people who make the difference.
At Fidia we strive every day to improve and evolve.

”

We are constantly evolving

We are a dynamic company and we open up new pathways in international markets, launch new products, and experiment with new approaches.

OUR FIGURES BY FOCUS AREA (%, 2023)
34,92 %
JOINT CARE
20,5 %
EYE CARE
13,69 %
SKIN CARE
13,67 %
PRIMARY CARE
6,76 %
SPECIALTY CARE
1,77 %
REGENERATIVE CARE
0,95 %
AESTHETIC CARE
7,74 %
OTHER
Our Group grows stronger
We are constantly evolving, including through important international acquisitions.
2024
Consolidating our ophthalmology presence in Italy
We have expanded the range of eye health products thanks to the acquisition of 100% of the ophthalmic business of Sanifarma s.r.l., a leading Italian company in the ocular health sector in pharmacies, also active in large-scale distribution and online channels. We have also strengthened our partnership with the multinational Novartis for Italian market distribution by adding 6 ophthalmological medicinal specialities for the treatment of glaucoma.
2023
Unipharm Polska
Fidia acquired some eye care products and a Vitamin D-based nutritional supplement along with a branch of the Polish affiliate of Unipharm, privately owned pharmaceutical company headquartered in the U.S. specializing in the development and marketing of over-the-counter (OTC) drugs and nutritional products.
2021
Strengthening our position in anti-inflammatory drugs
We signed an agreement for the acquisition of a large integrated portfolio of anti-inflammatory drugs commercialized in numerous international markets, thus strengthening Fidia’s presence in them.
2019
Strengthening our position in ophthalmology
We acquired three new ophthalmic products in the Spanish market from Novartis Farma, Spain, a Spanish subsidiary of the Novartis Pharma AG group of companies, Basel. This move is part of a project to strengthen the presence of Fidia in the national and international ophthalmic market, which began in 2017 with the acquisition of Sooft Italia.
2018
Soluciones Bioregenerativas SL
A company working in the sector of regenerative medicine within the field of osteoarticular health, aesthetics, dermatology and veterinary medicine, also thanks to the use of PRP (platelet-rich plasma).
2017
Sooft Italia S.p.A.
A leading player in the Italian ophthalmic market, with a complete range of over 100 products for eye health: medicines, supplements and medical devices.
2016
Biofarmitalia
Company specializes in novel technologies for cosmetic and pharmaceutical applications. Now an integral part of Fidia following a merger by incorporation in December 2019.

“

For us, innovation means studying, discovering, creating new solutions, continuously improving existing products.

”

Innovation is the gateway to the future

Also thanks to our well-established body of patents involving hyaluronic acid, our research never stops.

CLINICAL STUDIES ON HYALURONIC ACID
+310
PATENTS
~ 1,400

Media room

Press materials, images and videos of our company and institutional information.

Find out more
You are about to leave Fidia Pharma USA Inc.
All information you are about to see is related to a specific selected market, including the products’ portfolio, and therefore comply to different local regulations.
PROCEED
cta